Table 3.

Estimated cost savings for first financial year—2013–2014

Area of change	Estimated cost saving (£)
Additional clinic capacity, IT and specialist nurse	−60 000
Biologic cessation: disease remission	110 000
Primary non-responders*	44 000
Non-adherence with treatment/monitoring	44 000
Increased use of adalimumab vs infliximab	89 000
Transferred to research study	124 000
Activity income: colonoscopies	18 445
Follow-up appointments	41 216
Total savings	410 691

*Estimated one-third of yearly biologics treatment received.

IT, information technology.